Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i67-i75

  Sriskandarajah, Sanjeevan ^a   Aasarød, Knut ^b,c   Skrede, Steinar ^a,d   Knoop, Thomas ^a,d   Reisæter, Anna Varberg ^e   Bjørneklett, Rune ^a,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

ANCA associated glomerulonephritis; diagnostic delay; end stage renal disease; mortality; prognosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANCA ASSOCIATED GLOMERULONEPHRITIS; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NORWEGIAN (PEOPLE); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COMPLICATION; GLOMERULONEPHRITIS; NORWAY; YOUNG ADULT;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; GLOMERULONEPHRITIS; HUMANS; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84926618627     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv008     Document Type: Article

References (30)

1. Couser WG. Rapidly progressive glomerulonephritis: classification, patho-genetic mechanisms, and therapy. Am J Kidney Dis 1988; 11: 449-464
2. Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010; 21: 745-752
3. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-270
4. Aasarod K, Iversen BM, Hammerstrom J et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 2069
5. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70: 1415-1421
6. Jayne D. Challenges in the management of microscopic polyangiitis: past, present and future. Curr Opin Rheumatol 2008; 20: 3-9
7. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
8. Luqmani R, Suppiah R, Edwards CJ et al. Mortality in Wegener's granulo-matosis: a bimodal pattern. Rheumatology (Oxford) 2011; 50: 697-702
9. Slot MC, Tervaert JW, Franssen CF et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-677
10. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494
11. Gayraud M, Guillevin L, le Toumelin P et al. Long-term follow-up of poly-arteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-675
12. Gonzalez-Garcia A, R-Borlado L, Leonardo E et al. Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells. J Immunol 1997; 158: 4104-4112
13. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010; 363: 285-286
14. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophospha-mide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
15. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
16. Bomback AS, Appel GB, Radhakrishnan J et al. ANCA-associated glomer-ulonephritis in the very elderly. Kidney Int 2011; 79: 757-764
17. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituxi-mab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168
18. Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vascu-litis. Arthritis Rheum 2012; 64: 3760-3769
19. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429
20. Booth AD, Almond MK, Burns A et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-784
21. Hilhorst M, Wilde B, van Paassen P et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013; 28: 373-379
22. Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-266
23. Chen YX, Zhang W, Chen XN et al. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis. Clin Exp Rheumatol 2014; 32(3 Suppl 82): S5-S10
24. Tang W, Bose B, McDonald SP et al. The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol 2013; 8: 773-780
25. Basu N, McClean A, Harper L et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014; 73: 207-211
26. Lee T, Gasim A, Derebail VK et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 2014; 9: 905-913
27. Knoop T, Vikse BE, Svarstad E et al. Mortality in patients with IgA ne-phropathy. Am J Kidney Dis 2013; 62: 883-890
28. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 572-581
29. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. Nephrol Dial Transplant 2004; 19: 356-364
30. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 2014; 13: 723-729